Highest-materiality recent filing
Picard Medical CEO Patrick Schnegelsberg steps down; Chairman Richard Fang named interim CEO
Patrick NJ Schnegelsberg resigned as CEO and board member effective June 18, 2026; departure not related to any disagreement.
Picard Medical terminates CFO Bernard Skaggs; appoints Georgina Smith as CAO
Bernard Skaggs terminated as CFO, effective June 1, 2026.
Picard Medical Q1 revenue up 85%, gross margin 24%; NYSE listing notice received
Q1 2026 revenue $1.2M (+85% YoY); gross profit margin 24% vs. -58% in Q1 2025.
Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices
Revenue $1.2M (+85% YoY); gross profit $0.3M (24% margin) vs gross loss of $0.4M in Q1 2025.
Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity
Gross proceeds of $5.0M from sale of ~16.7M shares (or pre-funded warrants) and Series A/B warrants at $0.30 per unit.
Picard Medical prices $5M offering, exchanges high-price warrants for new $0.35 warrants
Gross proceeds ~$5M from selling 16.67M shares and common warrants at $0.30/unit.
Picard Medical Q1 preliminary revenue up 79.9% to $1.1M; driven by STAH sales
Preliminary unaudited revenue of $1.1M for Q1 2026 vs $0.6M in Q1 2025, a 79.9% increase.
Picard Medical FY2025 revenue $4.94M (+12.5% YoY); U.S. rev +33.5%
Revenue $4.94M (+12.5% YoY); U.S. revenue +33.5% to 88.25% of total.
Picard Medical FY2025 revenue up 12.5% to $4.9M, net loss widens to $27.0M
Revenue $4.94M (+12.5% YoY); product revenue $4.75M, 96% of total.
Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.
Issued $15M initial senior secured notes due Dec 26, 2028, at 0% annual interest, with option for up to $35M additional.
Patient at IVDK Dedinje Hospital (Belgrade, Serbia) reached 2,900 days on SynCardia Total Artificial Heart, longest ever recorded.
Emperor TAH uses identical blood-contacting materials as FDA-approved SynCardia STAH, replaces pneumatic driver with electromechanical system.
Picard Medical Q3 revenue up 35% to $1.19M; IPO nets $15.5M in September
Revenue $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss $3.36M vs $3.77M.
Picard Medical prices $17M IPO at $4/share; commences trading on NYSE American under PMI
4,250,000 shares sold at $4.00 for $17M gross proceeds; over-allotment option for 637,500 additional shares.
The Board appointed Richard Fang, Ph.D., 60, as the Company's Interim Chief Executive Officer, effective as of the Separation Date.
On June 17, 2026, Patrick NJ Schnegelsberg notified Picard Medical, Inc. (the "Company") of his decision to step down as Chief Executive Officer and as a member of the Board of Directors of the Company (the "Board"), effective June 18, 2026
The Board of Directors of the Company appointed Georgina Smith, 54, as the Company’s Chief Accounting Officer, effective June 1, 2026.
Bernard Skaggs was terminated as the Chief Financial Officer of Picard Medical, Inc. (the “Company”), effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material